APO-DIPYRIDAMOLE TABLET
Država: Kanada
Jezik: engleski
Izvor: Health Canada
Svojstava lijeka
(SPC)
10-08-2021
Neki dokumenti za ovaj proizvod trenutno nisu dostupni, možete poslati zahtjev u našu korisničku službu i mi ćemo vas obavijestiti čim ih budemo mogli dobiti.
Pošalji zahtjev.
Pošalji zahtjev.
Aktivni sastojci:
DIPYRIDAMOLE
Dostupno od:
APOTEX INC
ATC koda:
B01AC07
INN (International ime):
DIPYRIDAMOLE
Doziranje:
25MG
Farmaceutski oblik:
TABLET
Sastav:
DIPYRIDAMOLE 25MG
Administracija rute:
ORAL
Jedinice u paketu:
250ML
Tip recepta:
Prescription
Područje terapije:
MISCELLANEOUS VASODILATATING AGENTS
Proizvod sažetak:
Active ingredient group (AIG) number: 0106621001; AHFS:
Status autorizacije:
APPROVED
Datum autorizacije:
2021-08-12
Svojstava lijeka
Page 1 of 18
PRODUCT MONOGRAPH
PR
APO-DIPYRIDAMOLE
DIPYRIDAMOLE TABLETS USP
25, 50, 75 AND 100 MG
PR
APO-DIPYRIDAMOLE-SC
DIPYRIDAMOLE SUGAR-COATED TABLETS USP
25, 50 AND 75 MG
CORONARY VASODILATOR
INHIBITOR OF PLATELET ADHESION AND AGGREGATION
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
AUGUST 10, 2021
CONTROL NUMBER: 246833
Page 2 of 18
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
SUMMARY PRODUCT
INFORMATION......................................................................................
3
INDICATIONS AND CLINICAL USES
.........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................................
3
ADVERSE
REACTIONS.............................................................................................................
4
DRUG INTERACTIONS
.............................................................................................................
5
DOSAGE AND ADMINISTRATION
.............................................................................................
6
OVERDOSAGE..........................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
..............................................................................
6
STORAGE AND STABILITY
.......................................................................................................
7
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................................. 7
PART II: SCIENTIFIC INFORMATION
...........................................................................................
9
PHARMACEUTICAL INFORMATION
.............................................
Pročitajte cijeli dokument
